Ponvory is a once-daily oral selective sphingosine-1-phosphate receptor 1 modulator.
Specific vascular disease risk factors may be linked to disease progression and decreased brain phosphate metabolism in patients with multiple sclerosis.
The objective of this study was to evaluate whether a retinal SD-OCT assessment at baseline is associated with long-term disability worsening in people with MS over 10 years.
There may be numerous risk factors and outcomes associated with SARS-CoV-2 infection in patients with multiple sclerosis.
PoNS is a portable, noninvasive, prescription-only device intended to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older.
Investigators sought to better understand the pathological correlates associated with increased serum GFAP in the normal appearing white matter of patients with multiple sclerosis.
Study researchers examined whether baseline MRI-markers and demographic and clinical data can help predict cognitive worsening patients with multiple sclerosis.
Ambulatory disability and older age are associated with worse clinical severity of COVID-19, including death, among patients with MS.
A team of researchers assessed the Novartis-Oxford Multiple Sclerosis data set to investigate the relationship between age, relapse frequency, and phenotypic presentation of multiple sclerosis.
Vascular comorbidity burden among patients with multiple sclerosis may be associated with neurologic dysfunction and neurodegeneration.